4-胍基-L-苯丙氨酸 | 59574-11-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4-胍基-L-苯丙氨酸
• 英文名称: 4-guanidino-phenylalanine
• 英文别名: p-Guanidino-L-Phe；p-Guanidino-L-phenylalanin；para-guanidino-L-phenylalanine；4-guanidino-DL-phenylalanine；4-Guanidinophenylalanine；(2S)-2-amino-3-[4-(diaminomethylideneamino)phenyl]propanoic acid
• CAS: 59574-11-7
• 化学式: C₁₀H₁₄N₄O₂
• 分子量: 222.247
• InChiKey: FYMNTAQFDTZISY-QMMMGPOBSA-N

物化性质

• 沸点：
  416.3±55.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  128
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-胍基-3-苯基丙酸 、 L-arginyl-L-phenylalanine 、 4-Guanidino-methylphenylalanine 、 苯丙氨酸酰肼 、 2-(2-amino-3-phenylpropanamido)-N-(naphthalen-2-yl)-5-guanidinopentanamide 、 H-Arg-Arg-Trp-Cys-Phe-Arg-Val-Cys-Tyr-Arg-Gly-Phe-Cys-Tyr-Arg-Lys-Cys-Arg-NH2 、 生成 4-胍基-L-苯丙氨酸
  参考文献：
  名称：

  DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO-OR NANOEMULSIFICATION

  摘要：

  本发明涉及溶解化合物、用于从油、脂肪、水乳液、水介质和有机溶液中溶解和去除羧酸，特别是脂肪酸的装置和方法。采用本发明方法的装置将用于通过制备羧酸特别是脂肪酸和含有至少一种氨基甲酰基和/或肼基团的溶解化合物的水微观或纳米乳液，分离油、脂肪、水乳液、亲脂性介质或有机溶液中的羧酸。溶解化合物的溶解效果与本发明所述的羧酸分离方法相结合，可用于治疗需要去除脂肪酸或从血液中分析羧酸或处理食品、药品、化学、生物燃料工业或其他工业加工过程中的其他溶液的人员。

  公开号：

  US20130090488A1

文献信息

• CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS
  申请人：POLYPHOR AG

  公开号：US20150051183A1

  公开（公告）日：2015-02-19

  The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), inhibitory activity on enzymes or antimicrobial activity. In particular, these macrocycles show inhibitory activity on endothelin converting enzyme of subtype 1 (ECE-1) and/or the cysteine protease cathepsin S (CatS), and/or act as antagonists of the oxytocin (OT) receptor, thyrotropin-releasing hormone (TRH) receptor and/or leukotriene B4 (LTB4) receptor, and/or as agonists of the bombesin 3 (BB3) receptor, and/or show antimicrobial activity against at least one bacterial strain. Thus they are showing great potential as medicaments for a variety of diseases.

  公式（I）的构象受限、空间定义的大环环系统由三个不同的分子部分组成：模板A、构象调节剂B和桥C。由这种环系统I描述的大环可通过并行合成或溶液中或固相上的组合化学轻松制造。它们被设计用于与各种特定生物靶标类相互作用，例如在G蛋白偶联受体（GPCR）上的激动或拮抗活性，酶的抑制活性或抗菌活性。特别是，这些大环显示对亚型1的内皮素转化酶（ECE-1）和/或半胱氨酸蛋白酶卡特普辛S（CatS）的抑制活性，和/或作为催产素（OT）受体、促甲状腺释放激素（TRH）受体和/或白三烯B4（LTB4）受体的拮抗剂，和/或作为瘤胃素3（BB3）受体的激动剂，和/或对至少一种细菌菌株显示抗菌活性。因此，它们显示出作为各种疾病药物的巨大潜力。
• [EN] LIPOPEPTIDE COMPOUNDS FOR THE TREATMENT OF PAIN DISORDERS<br/>[FR] COMPOSÉS LIPOPEPTIDES DESTINÉS AU TRAITEMENT DE TROUBLES DE LA DOULEUR
  申请人：INST NAT SANTE RECH MED

  公开号：WO2018197666A1

  公开（公告）日：2018-11-01

  The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

  这项发明基于发现一种具有镇痛特性的新细菌化合物，可用作治疗内脏疼痛等疼痛疾病的新工具。研究参与益生菌大肠杆菌菌株Nissle 1917（EcN）镇痛特性的机制，发明者表征了EcN产生的氨基脂肪酸，这些氨基脂肪酸显示出EcN的镇痛特性。其中一种化合物抑制了辣椒素诱导的结肠膨胀过敏，辣椒素是一种非常强力的伤害性化合物，通过GABA B受体发挥作用。此外，发明者证明了这种化合物能够穿过细胞上皮屏障（如肠上皮）。因此，该发明涉及一种源自γ-氨基丁酸的脂肽化合物。该发明还涉及根据该发明用于治疗疼痛障碍，如体表疼痛和内脏疼痛的脂肽化合物。
• [EN] MOLECULAR PROBES FOR DETECTING GRAM-NEGATIVE BACTERIA IN VITRO AND IN VIVO<br/>[FR] SONDES MOLÉCULAIRES POUR DÉTECTER DES BACTÉRIES GRAM NÉGATIF IN VITRO ET IN VIVO
  申请人：UNIV EDINBURGH

  公开号：WO2016075483A1

  公开（公告）日：2016-05-19

  A probe is provided comprising a label and a binding moiety, wherein the binding moiety is adapted to bind to gram-negative bacteria, and to substantially not bind to animal cells or gram-positive bacteria. A method of detecting the presence of bacteria in a target area is also provided, which allows the detection of bacteria generally, and the determination of whether that bacteria is gram negative or gram positive.

  提供一种探针，包括一个标签和一个结合基团，其中结合基团适用于结合革兰氏阴性细菌，并且基本不结合动物细胞或革兰氏阳性细菌。还提供了一种检测目标区域中细菌存在的方法，该方法允许通常检测细菌，并确定该细菌是革兰氏阴性还是革兰氏阳性。
• [EN] OPTICAL PROBE FOR THROMBIN<br/>[FR] SONDE OPTIQUE POUR THROMBINE
  申请人：UNIV COURT UNIV OF EDINBURGH

  公开号：WO2016151297A1

  公开（公告）日：2016-09-29

  Optical probes are presented, the probes comprising a first probe element, and a second probe element connected to a core. The first probe element comprises a first fluorophore connected to a first quencher by a first cleavable linker. The second probe element comprises a second fluorophore connected to a second quencher by a second cleavable linker. The first fluorophore is separated from the first quencher when the first cleavable linker is cleaved, and the second fluorophore is separated from the second quencher when the second cleavable linker is cleaved. Methods of detecting a first and second enzyme using the optical probe are also presented.

  光学探针包括第一探针元件和连接到核心的第二探针元件。第一探针元件包括第一荧光素通过第一可切割连接剂连接到第一猝灭剂。第二探针元件包括第二荧光素通过第二可切割连接剂连接到第二猝灭剂。当第一可切割连接剂被切割时，第一荧光素与第一猝灭剂分离，当第二可切割连接剂被切割时，第二荧光素与第二猝灭剂分离。还提供了使用光学探针检测第一和第二酶的方法。
• [EN] CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS MACROCYCLIQUES ENTIÈREMENT SYNTHÉTIQUES ET À CONFORMATION CONTRAINTE
  申请人：POLYPHOR AG

  公开号：WO2013139697A1

  公开（公告）日：2013-09-26

  The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), inhibitory activity on enzymes or antimicrobial activity. In particular, these macrocycles show inhibitory activity on endothelin converting enzyme of subtype 1 (ECE-1 ) and/or the cysteine protease cathepsin S (CatS), and/or act as antagonists of the oxytocin (OT) receptor, thyrotropin-releasing hormone (TRH) receptor and/or leukotriene B4 (LTB4) receptor, and/or as agonists of the bombesin 3 (BB3) receptor, and/or show antimicrobial activity against at least one bacterial strain. Thus they are showing great potential as medicaments for a variety of diseases.

  公式（I）的构象受限、空间定义明确的大环环形系统由三个不同的分子部分构成：模板A、构象调制剂B和桥梁C。由该环系统I描述的大环可通过溶液中的并行合成或组合化学，或者在固相上制造。它们被设计用来与各种特定生物靶标类相互作用，例如在G蛋白偶联受体（GPCR）上的激动或拮抗活性，对酶的抑制活性或抗菌活性。特别是，这些大环显示对第1亚型内皮素转化酶（ECE-1）和/或半胱氨酸蛋白酶S（CatS）的抑制活性，和/或作为催产素（OT）受体、促甲状腺释放激素（TRH）受体和/或白三烯B4（LTB4）受体的拮抗剂，和/或作为瘤胃肽3（BB3）受体的激动剂，和/或对至少一种细菌菌株显示抗菌活性。因此，它们显示出作为各种疾病药物的巨大潜力。